Knott David M Jr Avadel Pharmaceuticals PLC Transaction History

Knott David M Jr

$251 Million
Q2 2024

A detailed history of Knott David M Jr transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Knott David M Jr holds 333,000 shares of AVDL stock, worth $5.09 Million. This represents 1.87% of its overall portfolio holdings.

Number of Shares

333,000

Previous 333,000 -0.0%

Holding current value

$5.09 Million

Previous $5.62 Million 16.75%

% of portfolio

1.87%

Previous 1.99%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$12.55 - $17.22 $1.02 Million - $1.4 Million	81,150 Added 32.22%	333,000 $5.62 Million
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $289,200 - $437,700	30,000 Added 13.52%	251,850 $3.56 Million
Q3 2023 Nov 13, 2023	SELL	$10.3 - $15.99 $193,423 - $300,276	-18,779 Reduced 7.8%	221,850 $2.29 Million
Q2 2023 Aug 11, 2023	SELL	$8.48 - $16.48 $428,104 - $831,976	-50,484 Reduced 17.34%	240,629 $3.97 Million
Q1 2023 May 11, 2023	SELL	$6.41 - $9.95 $122,674 - $190,423	-19,138 Reduced 6.17%	291,113 $2.67 Million
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $404,662 - $806,100	-80,610 Reduced 20.62%	310,251 $2.22 Million
Q3 2022 Nov 10, 2022	BUY	$2.57 - $7.31 $429,398 - $1.22 Million	167,081 Added 74.66%	390,861 $1.96 Million
Q2 2022 Aug 11, 2022	BUY	$1.07 - $6.95 $17,245 - $112,013	16,117 Added 7.76%	223,780 $546,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $275,921 - $418,935	-50,535 Reduced 19.57%	207,663 $1.42 Million
Q4 2021 Feb 11, 2022	BUY	$7.34 - $11.18 $1.9 Million - $2.89 Million	258,198 New	258,198 $2.09 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

7.03M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $927M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.

Account